RT Journal Article SR Electronic T1 Correlations between per capita green tea consumption and COVID-19 morbidity/mortality: comparing the strength before and after Omicron emergence JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.12.18.23300136 DO 10.1101/2023.12.18.23300136 A1 Storozhuk, Maksim YR 2024 UL http://medrxiv.org/content/early/2024/09/27/2023.12.18.23300136.abstract AB Purpose There is rapidly growing in vitro pharmacological evidence suggesting preventive/therapeutic potential of green tea and its constituent EGCG in battle with COVID-19. The aim of this study was to analyze time course of previously reported correlations between per capita green tea consumption and COVID-19 morbidity/mortality with a focus on comparing periods of time before (year 2021) and after (years 2022-2024) emergence of Omicron variant.Methods Correlations between per capita green tea consumption and COVID-19 morbidity/mortality were calculated using multiple regression models in a subset (n=84) of countries/territories worldwide with HDI above 0.55. Strength of the correlations for several dates in 2021 - 2024 was compared.Results Higher per capita green tea consumption was associated with lower COVID-19 morbidity and mortality. Statistically significant correlations were observed in 2021, 2022, 2023 and 2024. As compared to 2021, the strength of both correlations was decreased during 2022-2024 period. On average normalized to 2021 strength of correlation between per capita green tea consumption and COVID-19 morbidity decreased to 0.60, while normalized strength of correlation between per capita green tea consumption and COVID-19 mortality decreased to 0.83.Conclusion Overall, the results of this study are in line with in vitro pharmacological evidence. Though indirectly, these results at epidemiological level support the idea that green tea consumption may have not only preventive, but also therapeutic value in relation to COVID-19. Nevertheless, because of limitations of this study, this idea still should be considered as a hypothesis requiring further assessment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData (mostly) available within the article or its supplementary materials. Additional data available on request from the author.